Krystal Biotech, Inc.

As of June 30, 2026, Krystal Biotech, Inc. carries a market capitalization of 9.78B, placing it among publicly traded companies globally. Its enterprise value stands at 9.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Krystal Biotech, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Krystal Biotech, Inc. has 29.60M shares outstanding.

As of June 30, 2026, Krystal Biotech, Inc. trades at a trailing price-to-earnings ratio of 45.66. The price-to-sales ratio is 25.03, and the price-to-book ratio stands at 8.22.

As of June 30, 2026, Krystal Biotech, Inc. trades at an EV/EBITDA multiple of 50.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 23.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 52.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.04B versus a market cap of 9.78B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Krystal Biotech, Inc. maintains a current ratio of 8.32, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. posted a return on equity (ROE) of 20.12, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 18.30, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.33M in revenue per employee across its workforce of 290.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.62 indicates how many times Krystal Biotech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. recorded an income tax benefit of -12.99M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 198.36M, leaving 211.35M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Krystal Biotech, Inc.'s stock has gained approximately 72.05% over the past 52 weeks. The 50-day moving average sits at 294.21, while the 200-day moving average is 265.16.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. generated 385.56M in revenue and converted that into 211.35M in net income, yielding earnings per share of 6.97. EBITDA reached 178.93M, while operating income came in at 173.09M.

As of June 30, 2026, Krystal Biotech, Inc. holds 740.18M in cash and equivalents against 7.75M in total debt, resulting in a net debt position of -374.40M. Total book value stands at 1.19B, with working capital of 816.00M providing operational flexibility.

Krystal Biotech, Inc. produced 238.38M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.74M in capital expenditures, free cash flow totaled 225.64M - equivalent to 7.72 per share.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. posted a gross margin of 94.64, reflecting its pricing power and cost economics. The operating margin of 44.89 and net profit margin of 54.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.25, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.21, meaning Krystal Biotech, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Krystal Biotech, Inc. has an Altman Z-Score of 48.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.